Hydroxyprogesterone heptanoate


Hydroxyprogesterone heptanoate, also known as hydroxyprogesterone enanthate and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations. OHPH is given by injection into muscle at regular intervals.
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate.
OHPH was first described by 1954 and was introduced for medical use by 1957. It has been used clinically in France and Monaco in the past but is no longer marketed.

Medical uses

OHPH is a progestogen and was used in situations in which progestogens were indicated.

Available forms

OHPH was provided as a 125 mg/1 mL oil solution for use by intramuscular injection. In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations. It was used in Tocogestan, a combination of 50 mg progesterone, 200 mg OHPH, and 250 mg α-tocopherol palmitate in oil solution for use by intramuscular injection. It was also used in Triormon Depositum and Trioestrine Retard. OHPH was a component of the experimental preparation Trophobolene, which also contained estrapronicate and nandrolone undecanoate, as well.

Pharmacology

Pharmacodynamics

OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. The progestogenic potency of OHPH in the uterus is equal to or greater than that of progesterone when administered by subcutaneous injection in animals. Its potency in animals likewise appears to be similar to that of hydroxyprogesterone caproate.

Pharmacokinetics

OHPH shows a pronounced depot effect when administered by subcutaneous injection in animals, similarly to the closely related medication hydroxyprogesterone caproate. The oral activity of OHPH in animals does not appear to have been assessed.

Chemistry

OHPH, also known as hydroxyprogesterone enanthate, as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. It is a progestogen ester; specifically, it is the C17α heptanoate ester of 17α-hydroxyprogesterone. Analogues of OHPH include the more well-known medications hydroxyprogesterone acetate and hydroxyprogesterone caproate. The C3 benzilic acid hydrazone of OHPH, hydroxyprogesterone heptanoate benzilic acid hydrazone, is known and has been studied in animals. In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additional carbon in its fatty acid ester chain.

History

OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954. It was introduced for medical use by 1957. OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed.

Society and culture

Brand names

OHPH has been marketed alone under a number of brand names including H.O.P, Hydroxyprogesterone, Lutogil A.P., and Lutogyl A.P.

Availability

OHPH was previously marketed in France and Monaco but is no longer available.